XIST
DEVA
Market cap255mUSD
Nov 12, Last price
62.90TRY
Name
Deva Holding AS
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Deva Holding A.S. is a Turkish pharmaceutical firm specializing in the development and distribution of a wide array of medicinal goods. Its extensive portfolio encompasses treatments for various conditions, including cancer (antineoplastic agents), immune system disorders (immunomodulating agents), skin ailments (dermatological products), hormonal imbalances (systemic hormonal preparations), and infectious or parasitic diseases (anti-infective and antiparasitic products for systemic use). Additionally, the company offers dietary supplements and electrolyte solutions. Deva Holding also supplies pharmaceuticals targeting major bodily systems such as the urogenital and reproductive systems, blood and hematopoietic organs, the cardiovascular system, musculoskeletal system, nervous system, digestive tract and metabolism, respiratory system, and sensory organs. Furthermore, its offerings include specific drug classes like cephalosporins and penicillin, inhalation therapies, both solid and liquid oncological preparations, and veterinary pharmaceuticals. It also produces active pharmaceutical ingredients (APIs), various sterile dosage forms such as ampoules, liquid and lyophilized vials, and ophthalmic drops, alongside medical ampoules for sterile injectables; cologne is also part of its product line. Beyond its domestic operations, Deva Holding exports its products to approximately 60 nations globally. Established in 1958, the company maintains its headquarters in Istanbul, Turkey, and operates as a subsidiary of Eastpharma S.à R.L.
Key people
Chairman of the Board, Chairman of the Management Board, Chief Executive Officer · since 2009
Vice Chairman of the Board - Representing Vetas Veteriner ve Tarim Ilaclari AS, Vice General Manager - Finance · since 2009
Riza Yildiz
Financial Reporting and Accounting Director
Dogan Varinlioglu
Marketing and Sales Director
Aysecik Haas
Member of the Board
Tuncay Cem Akkus
Independent Member of the Board
Cuneyt Demirgures
Independent Member of the Board · since 2012
Headquarters & legal address
Halkalı Merkez Mh. Basın Ekspres Cad. No.1 Küçükçekmece
İSTANBUL 34303
TR
İSTANBUL 34303
TR
Valuation
Title TRY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||